Onco-Innovations Uplists to Cboe Canada

Audio By Carbonatix

TORONTO--(BUSINESS WIRE)--May 22, 2025--

Cboe Canada Inc. (“Cboe Canada”) is pleased to announce that Onco-Innovations Limited (“Onco”), a Canadian-based company dedicated to cancer research and treatment, has uplisted to Cboe Canada and is available for trading under the ticker symbol ONCO.

Onco has a core mission to prevent and cure cancer through cutting edge science. The company holds an exclusive global license to patented technology targeting solid tumors — and is now expanding into AI-driven analytics for multimodal real-world data.

“Onco-Innovations is at a pivotal stage,” said Thomas O’Shaughnessy, CEO of Onco. “Our growth now extends beyond drug development into AI-powered research, with a view to creating faster, smarter pathways to new cancer therapies. This convergence of science and technology positions Onco as a next-generation oncology company ready to tackle some of the biggest challenges in the field.”

“Joining Cboe is more than a listing — it’s a strategic alignment,” added O’Shaughnessy. “It gives us the tools to deepen investor engagement, expand our network, and accelerate our journey toward transforming the future of cancer therapy.”

Cboe Canada’s commitment to supporting innovative, high-growth companies and delivering global reach makes it a natural partner for Onco’s ambitious vision.

“It is an honour to welcome Onco to the growing roster of Cboe Listed issuers,” remarked Tanya Rowntree, Head of Listings at Cboe Canada. “Their move to a Tier 1 listing on Cboe reflects both their strategic growth trajectory and the confidence in our platform to support next-generation innovators. Onco now benefits from enhanced access to capital, greater liquidity, and increased visibility among investors and institutions alike.”

Investors can trade shares of ONCO through their usual investment channels, including discount brokerages and full-service dealers. To explore all listed securities on Cboe Canada, click here.

Cboe Canada is home to some of the most innovative Canadian and international growth companies, ETFs from Canada’s largest ETF issuers, and more than 120 Canadian Depositary Receipts (CDRs). Cboe consistently facilitates 15% of all volume traded in Canadian listed securities.

About Cboe Canada

Cboe Canada is Canada’s Tier 1 stock exchange providing a best-in-class listing experience for issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists companies and investment products seeking a robust and internationally recognized platform that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data.

Cboe Canada is part of Cboe Global Markets, the leading securities and derivatives exchange for the world stage. With exchanges in North America, Europe and Asia Pacific, Cboe is harnessing its global network to equip Issuers with essential capital markets solutions.

Connect with Cboe Canada: Website | LinkedIn | X | Instagram | Facebook

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco is focused on advancing personalized therapies that improve cancer outcomes and set new standards in oncology research.

Connect with Onco: Website | LinkedIn | X

View source version on businesswire.com:https://www.businesswire.com/news/home/20250522682046/en/

CONTACT: Cboe Canada Media:

[email protected]

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: RESEARCH TECHNOLOGY FINANCE PROFESSIONAL SERVICES DATA ANALYTICS HEALTH SCIENCE ONCOLOGY ARTIFICIAL INTELLIGENCE OTHER PROFESSIONAL SERVICES

SOURCE: Cboe Canada Inc.

Copyright Business Wire 2025.

PUB: 05/22/2025 10:00 AM/DISC: 05/22/2025 09:59 AM

http://www.businesswire.com/news/home/20250522682046/en